MTOR and hepatocellular carcinoma: Activating mutations of FGF19/CCND1 and PIK3CA, inactivating mutations of TSC1 or TSC2, and the homozygous deletion of PTEN can all activate the PI3K/AKT/mTOR and RAS/RAF/MAPK pathways in HCC [49].